NBC Las Vegas: AI is Accelerating Drug Discovery and Vaccine Development
In an NBC Las Vegas interview, Phil Mounteney, VP of Science and Technology at Dotmatics, explains how AI is transforming drug discovery and vaccine development by accelerating research timelines, reducing costs, enhancing drug safety through advanced data analysis, and optimizing development pipelines for faster and more efficient medical breakthroughs post-COVID.
How AI is Accelerating Drug Discovery and Vaccine Development
In a featured interview with NBC Las Vegas, Phil Mounteney, VP of Science and Technology at Dotmatics, explores how AI is revolutionizing drug discovery and vaccine development. From accelerating research timelines to reducing costs and improving drug safety, AI is playing a pivotal role in reshaping the industry post-COVID.
Phil highlights how AI-driven data analysis helps researchers quickly identify promising drug candidates, predict potential safety risks, and optimize development pipelines—all contributing to faster, safer, and more efficient medical breakthroughs.
Watch the full interview to discover how Dotmatics is driving innovation in life sciences and learn how AI is shaping the future of drug discovery.
Related
Gray TV Washington DC: AI helping scientists make drug breakthroughs
The Gray TV Washington DC feature highlights how scientists, including Christian Olsen of Dotmatics, are leveraging AI and machine learning to accelerate drug discovery and expedite bringing new drugs to market.
KRON TV: AI in Medicine From Research Assistant to Predictive Partner
In a KRON-TV interview, Dotmatics VP Phil Mounteney discusses how AI is evolving from a research assistant automating data tasks to a predictive partner that accelerates drug discovery by identifying new targets, designing molecules, and enabling personalized therapies, ultimately reducing costs and time to market while expanding patient access to safer, tailored medicines.
How AI is Transforming Drug Discovery
Dotmatics executives Kalim Saliba and Steve Tharp explain in an NBC News Boston feature how AI is revolutionizing drug discovery by enabling researchers to navigate complex data more efficiently, significantly reducing development time and costs, and accelerating the creation of safer, personalized medicines.
The Future of AI in Drug Discovery
The Forbes article discusses how AI is revolutionizing drug discovery by accelerating R&D and improving decision-making, highlighting Dotmatics’ role in integrating data and applying AI to scientific workflows, while also connecting these advancements to broader innovations in sustainability and global problem-solving.
NBC Louisiana: How AI is Accelerating Drug Discovery
In an NBC Louisiana feature, Dotmatics’ VP Phil Mounteney explained how AI is revolutionizing drug discovery by significantly reducing development time from up to ten years to potentially half, enhancing efficiency in analyzing vast data sets while ensuring data privacy by keeping sensitive information secure and in-house.
NBC News: How AI is Transforming Drug Discovery
In an NBC News segment, Alister Campbell, VP of Dotmatics, explains how the company leverages AI to analyze large datasets, predict effective drug compounds, and streamline fragmented data systems and manual workflows, thereby accelerating and improving the efficiency of drug discovery.